Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M25-275 ABBV-453 Monotherapy Dose Escalation in Relapsed/Refractory Multiple Myeloma (Japan Substudy 2)
jRCT2031250126Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surzetoclax in multiple myeloma (MM), sponsored by AbbVie Inc. Primary endpoint: Dose-Limiting Toxicities (DLTs) of ABBV-453. Started May 2025; status: recruiting.
02
Drugs
surzetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031250126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250126.